Obtenga las últimas noticias sobre las acciones de TransCode Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de RNAZ

Últimas noticias sobre

TRANSCODE THERAPEUTICS INC

TransCode Therapeutics

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

New,York,Ny - usa-may,5,,2015,Packages,Of,Tyson,Brand,Chicken

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

HSIC

RNAZ

Tyson, Ford, Cummins y otras empresas importantes publican resultados clave hoy. ¿Qué esperar de estas acciones en Wall Street?

Acciones a vigilar este lunes en Wall Street: Tyson, Cummins, Ford y más

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

Offerings

Press Releases

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

LXRX

PRSO

PRTG

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Alzamend Neuro

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cosciens Biopharma

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

enGene Holdings

Ernexa Therapeutics

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals

IN8bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Sunshine Biopharma

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Comments

TransCode Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL